Animal studyJournal of Orthopaedic Research, 2003
Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth.Staresinic M, Sebecic B et al.
In rats with a transected Achilles tendon, BPC 157 treatment was associated with better biomechanical, functional, microscopic and macroscopic healing than saline, and the peptide opposed a growth-inhibiting aldehyde in cultured tendon cells.
Cell studyJournal of Applied Physiology, 2011
The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration.Chang CH, Tsai WC et al.
In rat tendon explants and cultured tendon fibroblasts, BPC 157 increased outgrowth, survival under oxidative stress and migration, effects the authors link to activation of the FAK-paxillin pathway.
MechanismJournal of Molecular Medicine, 2017
Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation.Hsieh MJ, Liu HT et al.
BPC 157 promoted blood-vessel formation in chick membrane and endothelial tube-formation assays and sped blood-flow recovery in rat hind-limb ischemia, in association with VEGFR2 up-regulation and VEGFR2-Akt-eNOS signalling.
ReviewGut and Liver, 2020
Stable Gastric Pentadecapeptide BPC 157, Robert's Stomach Cytoprotection/Adaptive Cytoprotection/Organoprotection, and Selye's Stress Coping Response: Progress, Achievements, and the Future.Sikiric P, Hahm KB et al.
This review by the Sikiric group summarizes preclinical findings that BPC 157 protects the stomach and other tissues from injury and affects blood vessels, and discusses it as a possible mediator of cytoprotection.
Observational studyAlternative Therapies in Health and Medicine, 2021
Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain.Lee E, Padgett B
In a small retrospective chart review with telephone follow-up of 16 patients, most reported relief of knee pain after intra-articular BPC 157 (alone or combined with thymosin beta-4), although no validated outcome measures were used.
Human trialAlternative Therapies in Health and Medicine, 2024
Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study.Lee E, Walker C et al.
In an uncontrolled pilot of 12 women with interstitial cystitis who had not responded to pentosan polysulfate, all reported symptom improvement after a single procedure with BPC-157 injections around the bladder inflammation, with no adverse events reported.
Human trialAlternative Therapies in Health and Medicine, 2025
Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study.Lee E, Burgess K
Two adults given intravenous BPC-157 infusions showed no measurable changes in the tested heart, liver, kidney, thyroid or glucose biomarkers and reported no side effects, and the authors state larger studies are needed to confirm safety.
ReviewActa Orthopaedica Belgica, 2026
Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety.Poolton JT, Minett J et al.
This PRISMA systematic review found only three small human studies (30 participants in total), judged them to be of poor quality with very low certainty of evidence, and concluded BPC-157 should not be used clinically outside regulated, high-quality trials.
Regulatory documentFDA Pharmacy Compounding Advisory Committee briefing document, 2026
FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting, July 23-24, 2026: BPC-157-Related Bulk Drug Substances (BPC-157 free base and BPC-157 acetate)U.S. Food and Drug Administration (CDER review staff)
FDA staff evaluating BPC-157 free base and acetate for the 503A bulk drug substances list concluded that the balance of criteria weighs against listing them, citing characterization gaps and limited human safety information.